drugset / Trial / NCT07095465
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
NaSingle-groupOpen-labelTreatment
Summary
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Timeline
- Start
- 2025-11-14
- Primary completion
- 2029-02
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACP-204 | Unknown | 30 mg | Oral |
| Subject | ACP-204 | Unknown | 60 mg | Oral |